Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 10, 2017, Pages 2813-2816

  Natesan, Senthil ^a   Pai, Manjunath P ^b   Lodise, Thomas P ^c  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOLOZANE PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ARTICLE; CONTINUOUS INFUSION; CREATININE CLEARANCE; DOSE RESPONSE; KIDNEY FUNCTION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PSEUDOMONAS INFECTION; RENAL CLEARANCE; ANALOGS AND DERIVATIVES; CROSS INFECTION; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION TEST; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CROSS INFECTION; DRUG COMBINATIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FUNCTION TESTS; MALE; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; PENICILLANIC ACID; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 85030723349     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx221     Document Type: Article

References (17)

1. Package Insert. ZERBAXA (Ceftolozane and Tazobactam) for Injection, for Intravenous Use. Initial U.S., 2015
2. Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia. ClinicalTrials.gov Identifier: NCT01853982. https://clinicaltrials.gov/ct2/show/NCT01853982?termcefto lozane!and!tazobactam&rank6
3. Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) (ASPECT-NP). ClinicalTrials.gov Identifier: NCT02070757. https://clinicaltrials.gov/ct2/show/NCT02070757? termceftolozane!and!tazobactam&rank4
4. Farrell DJ, FlammRK, Sader HS et al. Antimicrobial activity of ceftolozanetazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012). Antimicrob Agents Chemother 2013; 57: 6305-10
5. Sader HS, Castanheira M, Flamm RK et al. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother 2014; 58: 1684-92
6. Sader HS, Farrell DJ, Castanheira M et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother 2014; 69: 2713-22
7. Chandorkar G, Xiao A, Mouksassi MS et al. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections. J Clin Pharmacol 2015; 55: 230-9
8. Cabot G, Bruchmann S, Mulet X et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 2014; 58: 3091-9
9. CraigWA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum b-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother 2013; 57: 1577-82
10. Martinez MN, Papich MG, Drusano GL. Dosing regimenmatters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 2012; 56: 2795-805
11. Lodise TP Jr, Patel N, Kwa A et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007; 51: 3510-5
12. Kaye KS, Pogue JM. Infections caused by resistant Gram-negative bacteria: epidemiology andmanagement. Pharmacotherapy 2015; 35: 949-62
13. VanScoy BD, Mendes RE, Castanheira M et al. Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model. Antimicrob Agents Chemother 2014; 58: 6024-31
14. Chandorkar G, Huntington JA, GotfriedMH et al. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother 2012; 67: 2463-9
15. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on b-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26: 1320-32
16. Xiao AJ, Caro L, Popejoy MWet al. PK/PD target attainment with ceftolozane/tazobactam using Monte Carlo simulation in patients with various degrees of renal function, including augmented renal clearance and end-stage renal disease. Infect Dis Ther 2017; 6: 137-48
17. Roberts JA, Abdul-Aziz MH, Lipman J et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14: 498-509